In the life sciences industry, operations and maintenance professionals understand critical equipment failure is inevitable. Risks may include significant downtime and scheduling bottlenecks for production, introduced stress for engineering and repair crews, and reduced effectivness in metrics such as Planned Production Time and Overall Equipment Availability (OEA). At NEXA, we have noted that a higher than acceptable exposure to workflow slowdowns stem from a simple lack of spare parts, identified at the critical juncture, and often too late. However, this risk can be mitigated beginning with the most high-volume cross department use areas, by drilling down on what may appear to be low ROI work and solving the problem.

Many large pharmaceutical companies worldwide have faced these issues—however, it does not need to be an acceptable cost of doing business, particularly for an industry that is providing life-saving and life-enhancing products. If companies recognize and work to resolve Mean Time To Repair (MTTR), using a targeted Spare Parts Program Review (SPPR), they can improve efficiency and implement a high-quality process to ensure production remains on track, and schedules intact.